Business Context and Reporting Period
Matinas Biopharma Holdings, Inc. filed this Form 8-K on September 12, 2016, to report the final closing of a private placement offering of Series A Preferred Stock to accredited investors.
Key Financial Metrics
- Gross Proceeds: $8.0 million from the sale of 1,600,000 Series A Preferred Shares at $5.00 per share.
- Net Proceeds: Approximately $6.9 million after deducting placement agent fees and estimated offering expenses.
- Placement Agent Fees: $800,000 cash fee plus a $240,000 non-accountable expense allowance.
- Warrant Issuance: Warrants issued to the placement agent to purchase 1,600,000 shares of Common Stock at an exercise price of $0.50 per share.
Material Changes
This filing represents a discrete capital raise event rather than a periodic financial update. Consequently, the filing does not provide comparative revenue, profit, cash flow, margin, or debt metrics versus prior periods. The primary material change is the increase in cash liquidity of approximately $6.9 million and the issuance of new equity securities.
Outlook, Risks, and Unusual Items
- Future Obligations: The Company entered into a three-year, non-exclusive finder's fee agreement with the placement agent (Aegis Capital Corp.) for potential future transactions (e.g., business combinations, joint ventures). Fees range from 2.5% to 5% of consideration paid.
- Right of First Refusal: The placement agent holds an irrevocable preferential right of first refusal to act as co-manager for future public or private offerings for 12 months following the closing.
- Related Party Transactions: Certain officers, directors, and affiliates of the placement agent purchased Series A Preferred Shares in this offering.
- Regulatory Status: The securities were issued pursuant to exemptions from registration under Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D and are restricted under Rule 144.
Investor Verification Checklist
- Verify the specific terms of the Series A Preferred Stock in the Certificate of Designations filed as Exhibit 3.1 to the August 1, 2016 Form 8-K.
- Confirm the exact amount of offering expenses deducted to arrive at the $6.9 million net proceeds figure.
- Review the full text of the Placement Agency Agreement to understand the scope of the finder's fee and right of first refusal.
- Assess the dilution impact of the 1,600,000 warrants issued to the placement agent with a low exercise price of $0.50.